Trials / Completed
CompletedNCT01787396
Phase III Trial to Evaluate the Efficacy and Safety of Initial Combination Therapy With Gemigliptin 50mg q.d and Metformin q.d
A Multicenter, Randomized, Active-controlled, Parallel Group, Double-blind, Phase III Trial to Evaluate the Efficacy and Safety of Initial Combination Therapy With Gemigliptin 50mg q.d and Metformin q.d Compared With Either Monotherapy in Treatment naïve Patients With Type 2 Diabetes
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 433 (actual)
- Sponsor
- LG Life Sciences · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate efficacy and safety of initial combination therapy with Gemigliptin 50mg q.d and Metformin q.d compared with either monotherapy in treatment naïve patients with type 2 diabetes, In other words, to proof superiority of initial combination therapy with Gemigliptin and Metformin than each monotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gemigliptin 50mg | |
| DRUG | Placebo(Metformin) | |
| DRUG | Metformin | |
| DRUG | Placebo(Gemigliptin) |
Timeline
- Start date
- 2013-04-01
- Primary completion
- 2015-03-01
- Completion
- 2015-03-01
- First posted
- 2013-02-08
- Last updated
- 2015-04-03
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01787396. Inclusion in this directory is not an endorsement.